{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:23:24Z","timestamp":1793622204681,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T00:00:00Z","timestamp":1664668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T00:00:00Z","timestamp":1664668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["7212157"],"award-info":[{"award-number":["7212157"]}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-I2M-1-029"],"award-info":[{"award-number":["2021-I2M-1-029"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803584"],"award-info":[{"award-number":["81803584"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703536"],"award-info":[{"award-number":["81703536"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Technology Major Projects for \u201cMajor New Drugs Innovation and Development\u201d","award":["2018ZX09711001-005-025"],"award-info":[{"award-number":["2018ZX09711001-005-025"]}]},{"name":"Technology Major Projects for \u201cMajor New Drugs Innovation and Development\u201d","award":["2018ZX09711001-012"],"award-info":[{"award-number":["2018ZX09711001-012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adrenocortical carcinoma (ACC) is an extremely rare, aggressive tumor with few effective therapeutic options or drugs. Mitotane (Mtn), which is the only authorized therapeutic drug, came out in 1970 and is still the only first-line treatment for ACC in spite of serious adverse reaction and a high recurrence rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>By in silico analysis of the ACC dataset in the cancer genome atlas (TCGA), we determined that high expression levels of cyclin-dependent kinase-1 (CDK1) were significantly related to the adverse clinical outcomes of ACC. In vitro and in vivo experiments were performed to evaluate the role of CDK1 in ACC progression through gain and loss of function assays in ACC cells. CDK1 inhibitors were screened to identify potential candidates for the treatment of ACC. RNA sequencing, co-immunoprecipitation, and immunofluorescence assays were used to elucidate the mechanism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overexpression of CDK1 in ACC cell lines promoted proliferation and induced the epithelial-to-mesenchymal transition (EMT), whereas knockdown of CDK1 expression inhibited growth of ACC cell lines. The CDK1 inhibitor, cucurbitacin E (CurE), had the best inhibitory effect with good time-and dose-dependent activity both in vitro and in vivo. CurE had a greater inhibitory effect on ACC xenografts in nude mice than mitotane, without obvious adverse effects. Most importantly, combined treatment with CurE and mitotane almost totally eliminated ACC tumors. With respect to mechanism, CDK1 facilitated the EMT of ACC cells via Slug and Twist and locked ACC cells into the G2\/M checkpoint through interaction with UBE2C and AURKA\/B. CDK1 also regulated pyroptosis, apoptosis, and necroptosis (PANoptosis) of ACC cells through binding with the PANoptosome in a ZBP1-dependent way.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CDK1 could be exploited as an essential therapeutic target of ACC via regulating the EMT, the G2\/M checkpoint, and PANoptosis. Thus, CurE may be a potential candidate drug for ACC therapy with good safety and efficacy, which will meet the great need of patients with ACC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-022-03641-y","type":"journal-article","created":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T18:02:27Z","timestamp":1664733747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial\u2013mesenchymal transition, G2\/M phase transition, and PANoptosis"],"prefix":"10.1186","volume":"20","author":[{"given":"Liwen","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanhua","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-0787","authenticated-orcid":false,"given":"Jinhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,2]]},"reference":[{"key":"3641_CR1","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1210\/er.2013-1029","volume":"35","author":"T Else","year":"2014","unstructured":"Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ, Hammer GD. Adrenocortical carcinoma. Endocr Rev. 2014;35:282\u2013326.","journal-title":"Endocr Rev"},{"key":"3641_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41574-019-0221-7","volume":"15","author":"J Crona","year":"2019","unstructured":"Crona J, Beuschlein F. Adrenocortical carcinoma\u2014towards genomics guided clinical care. Nat Rev Endocrinol. 2019;15:548\u201360.","journal-title":"Nat Rev Endocrinol"},{"key":"3641_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101415","volume":"34","author":"S Puglisi","year":"2020","unstructured":"Puglisi S, Calabrese A, Basile V, Pia A, Reimondo G, Perotti P, Terzolo M. New perspectives for mitotane treatment of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2020;34: 101415.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"3641_CR4","doi-asserted-by":"publisher","first-page":"R105","DOI":"10.1530\/JME-18-0122","volume":"62","author":"JFH Pittaway","year":"2019","unstructured":"Pittaway JFH, Guasti L. Pathobiology and genetics of adrenocortical carcinoma. J Mol Endocrinol. 2019;62:R105\u201319.","journal-title":"J Mol Endocrinol"},{"key":"3641_CR5","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1080\/15384101.2018.1491236","volume":"17","author":"R Prevo","year":"2018","unstructured":"Prevo R, Pirovano G, Puliyadi R, Herbert KJ, Rodriguez-Berriguete G, O\u2019Docherty A, Greaves W, McKenna WG, Higgins GS. CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner. Cell Cycle. 2018;17:1513\u201323.","journal-title":"Cell Cycle"},{"key":"3641_CR6","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1093\/annonc\/mdv264","volume":"26","author":"BH O'Neil","year":"2015","unstructured":"O\u2019Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, et al. A phase II\/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol. 2015;26:1923\u20139.","journal-title":"Ann Oncol"},{"key":"3641_CR7","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1158\/1078-0432.CCR-20-4730","volume":"27","author":"J Wu","year":"2021","unstructured":"Wu J, Yuan Y, Long Priel DA, Fink D, Peer CJ, Sissung TM, Su YT, Pang Y, Yu G, Butler MK, et al. Phase I study of zotiraciclib in combination with temozolomide for patients with recurrent high-grade astrocytomas. Clin Cancer Res. 2021;27:3298\u2013306.","journal-title":"Clin Cancer Res"},{"key":"3641_CR8","doi-asserted-by":"publisher","first-page":"758","DOI":"10.2174\/1871520620666200203125712","volume":"20","author":"S Izadi","year":"2020","unstructured":"Izadi S, Nikkhoo A, Hojjat-Farsangi M, Namdar A, Azizi G, Mohammadi H, Yousefi M, Jadidi-Niaragh F. CDK1 in breast cancer: implications for theranostic potential. Anticancer Agents Med Chem. 2020;20:758\u201367.","journal-title":"Anticancer Agents Med Chem"},{"key":"3641_CR9","doi-asserted-by":"publisher","first-page":"6561","DOI":"10.1158\/0008-5472.CAN-18-0330","volume":"78","author":"D Ravindran Menon","year":"2018","unstructured":"Ravindran Menon D, Luo Y, Arcaroli JJ, Liu S, KrishnanKutty LN, Osborne DG, Li Y, Samson JM, Bagby S, Tan AC, et al. CDK1 Interacts with Sox2 and promotes tumor initiation in human melanoma. Cancer Res. 2018;78:6561\u201374.","journal-title":"Cancer Res"},{"key":"3641_CR10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.tcb.2020.07.003","volume":"30","author":"B Bakir","year":"2020","unstructured":"Bakir B, Chiarella AM, Pitarresi JR, Rustgi AK. EMT, MET, plasticity, and tumor metastasis. Trends Cell Biol. 2020;30:764\u201376.","journal-title":"Trends Cell Biol"},{"key":"3641_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","volume":"29","author":"I Pastushenko","year":"2019","unstructured":"Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29:212\u201326.","journal-title":"Trends Cell Biol"},{"key":"3641_CR12","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108647","volume":"40","author":"S Brabletz","year":"2021","unstructured":"Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021;40: e108647.","journal-title":"EMBO J"},{"key":"3641_CR13","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/med.21398","volume":"36","author":"B Ke","year":"2016","unstructured":"Ke B, Tian M, Li J, Liu B, He G. Targeting programmed cell death using small-molecule compounds to improve potential cancer therapy. Med Res Rev. 2016;36:983\u20131035.","journal-title":"Med Res Rev"},{"key":"3641_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fcimb.2020.00238","volume":"10","author":"P Samir","year":"2020","unstructured":"Samir P, Malireddi RKS, Kanneganti TD. The PANoptosome: a deadly protein complex driving pyroptosis, apoptosis, and necroptosis (PANoptosis). Front Cell Infect Microbiol. 2020;10:238.","journal-title":"Front Cell Infect Microbiol"},{"key":"3641_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/imr.12909","volume":"297","author":"M Zheng","year":"2020","unstructured":"Zheng M, Kanneganti TD. The regulation of the ZBP1-NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis). Immunol Rev. 2020;297:26\u201338.","journal-title":"Immunol Rev"},{"key":"3641_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.it.2017.11.002","volume":"39","author":"T Kuriakose","year":"2018","unstructured":"Kuriakose T, Kanneganti TD. ZBP1: Innate sensor regulating cell death and inflammation. Trends Immunol. 2018;39:123\u201334.","journal-title":"Trends Immunol"},{"key":"3641_CR17","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98\u2013102.","journal-title":"Nucleic Acids Res"},{"key":"3641_CR18","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/bioinformatics\/btt085","volume":"29","author":"N Gehlenborg","year":"2013","unstructured":"Gehlenborg N, Noble MS, Getz G, Chin L, Park PJ. Nozzle: a report generation toolkit for data analysis pipelines. Bioinformatics. 2013;29:1089\u201391.","journal-title":"Bioinformatics"},{"key":"3641_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1476-5586(04)80047-2","volume":"6","author":"DR Rhodes","year":"2004","unstructured":"Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6:1\u20136.","journal-title":"Neoplasia"},{"key":"3641_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"DS Chandrashekar","year":"2017","unstructured":"Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, Varambally S. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:649\u201358.","journal-title":"Neoplasia"},{"key":"3641_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nature18629","volume":"535","author":"X Liu","year":"2016","unstructured":"Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, Lieberman J. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016;535:153\u20138.","journal-title":"Nature"},{"key":"3641_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109595","volume":"121","author":"Y Fang","year":"2020","unstructured":"Fang Y, Tian S, Pan Y, Li W, Wang Q, Tang Y, Yu T, Wu X, Shi Y, Ma P, Shu Y. Pyroptosis: a new frontier in cancer. Biomed Pharmacother. 2020;121: 109595.","journal-title":"Biomed Pharmacother"},{"key":"3641_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12414","author":"Z Liu","year":"2017","unstructured":"Liu Z, Gan L, Xu Y, Luo D, Ren Q, Wu S, Sun C. Melatonin alleviates inflammasome-induced pyroptosis through inhibiting NF-kappaB\/GSDMD signal in mice adipose tissue. J Pineal Res. 2017. https:\/\/doi.org\/10.1111\/jpi.12414.","journal-title":"J Pineal Res"},{"key":"3641_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12943-019-1029-8","volume":"18","author":"Y Gong","year":"2019","unstructured":"Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K, Cheng H, Jin K, Ni Q, Yu X, Liu C. The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019;18:100.","journal-title":"Mol Cancer"},{"key":"3641_CR25","doi-asserted-by":"publisher","first-page":"18276","DOI":"10.1074\/jbc.RA120.015924","volume":"295","author":"B Banoth","year":"2020","unstructured":"Banoth B, Tuladhar S, Karki R, Sharma BR, Briard B, Kesavardhana S, Burton A, Kanneganti TD. ZBP1 promotes fungi-induced inflammasome activation and pyroptosis, apoptosis, and necroptosis (PANoptosis). J Biol Chem. 2020;295:18276\u201383.","journal-title":"J Biol Chem"},{"key":"3641_CR26","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, Haak HR, Mihai R, Assie G, Terzolo M. European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2018;179:G1\u201346.","journal-title":"Eur J Endocrinol"},{"key":"3641_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11912-019-0773-7","volume":"21","author":"S Jasim","year":"2019","unstructured":"Jasim S, Habra MA. Management of adrenocortical carcinoma. Curr Oncol Rep. 2019;21:20.","journal-title":"Curr Oncol Rep"},{"key":"3641_CR28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1530\/ERC-12-0403","volume":"20","author":"M Jain","year":"2013","unstructured":"Jain M, Zhang L, He M, Zhang YQ, Shen M, Kebebew E. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Endocr Relat Cancer. 2013;20:361\u201370.","journal-title":"Endocr Relat Cancer"},{"key":"3641_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3389\/fendo.2020.00219","volume":"11","author":"R Liang","year":"2020","unstructured":"Liang R, Weigand I, Lippert J, Kircher S, Altieri B, Steinhauer S, Hantel C, Rost S, Rosenwald A, Kroiss M, et al. Targeted gene expression profile reveals CDK4 as therapeutic target for selected patients with adrenocortical carcinoma. Front Endocrinol (Lausanne). 2020;11:219.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3641_CR30","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1111\/jcmm.15102","volume":"24","author":"J Guo","year":"2020","unstructured":"Guo J, Gu Y, Ma X, Zhang L, Li H, Yan Z, Han Y, Xie L, Guo X. Identification of hub genes and pathways in adrenocortical carcinoma by integrated bioinformatic analysis. J Cell Mol Med. 2020;24:4428\u201338.","journal-title":"J Cell Mol Med"},{"key":"3641_CR31","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.2147\/OTT.S108485","volume":"9","author":"A Kulshrestha","year":"2016","unstructured":"Kulshrestha A, Suman S, Ranjan R. Network analysis reveals potential markers for pediatric adrenocortical carcinoma. Onco Targets Ther. 2016;9:4569\u201381.","journal-title":"Onco Targets Ther"},{"key":"3641_CR32","doi-asserted-by":"publisher","first-page":"4484","DOI":"10.7150\/jca.26698","volume":"9","author":"H Xiao","year":"2018","unstructured":"Xiao H, Xu D, Chen P, Zeng G, Wang X, Zhang X. Identification of five genes as a potential biomarker for predicting progress and prognosis in adrenocortical carcinoma. J Cancer. 2018;9:4484\u201395.","journal-title":"J Cancer"},{"key":"3641_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12967-022-03277-y","volume":"20","author":"YG Huang","year":"2022","unstructured":"Huang YG, Li D, Wang L, Su XM, Tang XB. CENPF\/CDK1 signaling pathway enhances the progression of adrenocortical carcinoma by regulating the G2\/M-phase cell cycle. J Transl Med. 2022;20:78.","journal-title":"J Transl Med"},{"key":"3641_CR34","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.7150\/thno.32738","volume":"9","author":"D Jin","year":"2019","unstructured":"Jin D, Guo J, Wu Y, Du J, Wang X, An J, Hu B, Kong L, Di W, Wang W. UBE2C, directly targeted by miR-548e-5p, increases the cellular growth and invasive abilities of cancer cells interacting with the EMT marker protein zinc finger e-box binding homeobox 1\/2 in NSCLC. Theranostics. 2019;9:2036\u201355.","journal-title":"Theranostics"},{"key":"3641_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12943-020-01305-3","volume":"20","author":"R Du","year":"2021","unstructured":"Du R, Huang C, Liu K, Li X, Dong Z. Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy. Mol Cancer. 2021;20:15.","journal-title":"Mol Cancer"},{"key":"3641_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101434","volume":"34","author":"B Altieri","year":"2020","unstructured":"Altieri B, Ronchi CL, Kroiss M, Fassnacht M. Next-generation therapies for adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2020;34: 101434.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"3641_CR37","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.0c05551","author":"P Yang","year":"2020","unstructured":"Yang P, Liu W, Fu R, Ding GB, Amin S, Li Z. Cucurbitacin E chemosensitizes colorectal cancer cells via mitigating TFAP4\/Wnt\/beta-catenin signaling. J Agric Food Chem. 2020. https:\/\/doi.org\/10.1021\/acs.jafc.0c05551.","journal-title":"J Agric Food Chem"},{"key":"3641_CR38","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00432-009-0698-x","volume":"136","author":"C Sun","year":"2010","unstructured":"Sun C, Zhang M, Shan X, Zhou X, Yang J, Wang Y, Li-Ling J, Deng Y. Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling. J Cancer Res Clin Oncol. 2010;136:603\u201310.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3641_CR39","first-page":"697","volume":"42","author":"PC Hsu","year":"2019","unstructured":"Hsu PC, Tian B, Yang YL, Wang YC, Liu S, Urisman A, Yang CT, Xu Z, Jablons DM, You L. Cucurbitacin E inhibits the yes-associated protein signaling pathway and suppresses brain metastasis of human nonsmall cell lung cancer in a murine model. Oncol Rep. 2019;42:697\u2013707.","journal-title":"Oncol Rep"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03641-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03641-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03641-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T18:02:56Z","timestamp":1664733776000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03641-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,2]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3641"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03641-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,2]]},"assertion":[{"value":"23 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal study was reviewed and approved by the Institute of Animal Care and Use Committee at the Chinese Academy of Medical Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"444"}}